Sanofi has narrowed down the field of potential buyers for its generics business to drug companies from Brazil and India, plus several private equity funds, Reuters reports, citing sources. The deal could fetch $2.4 billion.Original Article
With private equity bidders lined up, Sanofi’s EU generics could go for up to $2.4B: Reuters
